About the Company

Addex Therapeutics (SIX: ADXN.SW) is a clinical-stage biotechnology company focused on the development of allosteric modulators to treat a wide range of central nervous system (CNS) disorders. The Company’s lead program is dipraglurant for the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease (PD). PD affects approximately 1.5% of people over the age of 65. As the disease progresses, the majority of patients will progress to having some degree of dyskinesia during peak levodopa exposure. Addex has successfully completed a Phase II study of dipraglurant with support from the Michael J. Fox Foundation and expects to launch a pivotal Phase III study in the second half of 2017.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research